?Aggressive Care at the End of Life; Where Are We

Faculty Medicine Year: 2019
Type of Publication: ZU Hosted Pages:
Authors:
Journal: Indian Journal of Palliative Care Wolters Kluwer - Medknow Volume:
Keywords : ?Aggressive Care , , , , Life; Where , ,    
Abstract:
Background: Although, efforts to encourage palliative care only for terminal patients, aggressive end‑of‑life care (EOL) care still common for those probably to die shortly. Aim: Multicenter experiences to investigate where did we stand in this era? Patients and Methods: A retrospective study included patients with advanced solid tumors. The presence of one or more of the following indicators in the last month of life (LM) referred to aggressive EOL care: emergency department (ED) visits ≥ twice, admission to the hospital through ED, death in critical care units (CCUs), and palliative chemotherapy (PC) at the past 2 weeks before death. Results: A total of 435 patients, 51.5% were men with a median age of 62 years (range: 17–108), were included in the study. Most of the patients (89.2%) belonged to Group II; they had attended ED at least twice (60%), approximately 53% admitted to the hospital through ED, 31% received PC‑LM with 41% of them had at the past 2 weeks before death, 13% died in the CCUs, and more than half of them (53%) survived <2 weeks. Kaplan–Meier estimator revealed that median survival was 30 days in Group I versus 13 days in Group II (odds ratio: 1.63; 95% confidence interval: 1.20–2.21; P = 0.002). The median survival was statistically significantly associated with PC‑LM ≥14 days and the admission mode. There was no statistically significant association with age, sex, and primary cancer sites. Conclusion: The majority of our patients continue with anticancer treatments they possibly do not need and associated with poor survival.
   
     
 
       

Author Related Publications

  • Amarallah Abdelmoneim Mohamed Sayed, "Myelodysplastic syndrome from theoretical review to clinical application view", PAGEPress, Italy, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Patterns of Inpatient Admissions during Haj Clinical conditions, length of stay and patient outcomes at an advanced care centre in Makkah, Saudi Arabia", Pak J Med Sci, 2018 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Neoadjuvant Platinum and Gemcitabine Regimens Precede Definitive Radiotherapy in Locally Advanced Bladder Cancer", Symbiosis, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Efficacy and Safety of First-Line Pazopanib in Patients with Metastatic Renal Cell Carcinoma: Real-Life Multi Institutional Experience", Remedy Publications LLC, 2019 More
  • Amarallah Abdelmoneim Mohamed Sayed, "CDK4/6 inhibitors in advanced breast cancer, what is beyond?", PAGEPress, Italy, 2019 More

Department Related Publications

  • Rasha Mohamed Mostafa Hagag, "Factors Affecting Survival in Egyptian Patients Suffering from Urinary Bladder Cancer: A Multicenter Retrospective Study", Journal of Cancer Science & Therapy, 2018 More
  • Rasha Mohamed Mostafa Hagag, "Assessment of initial real life experience with Abiraterone Acetate in patients with castrate resistant prostate cancer: A retrospective study in Saudi Arabian patients", International Journal of Advanced Researc h, 2015 More
  • Amarallah Abdelmoneim Mohamed Sayed, "Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed", Springer, 2016 More
  • Ola Mohamed Ahmed Elfarargy, ": Prevalence of Androgen Receptors expression in Triple Negative Breast Cancer Patients and its Correlation with Clinicopathological Criteria: Our Institutes experience", abs/10.1200/JCO.2017.35.15_suppl.e1258, 2017 More
  • Adel Salah Bakry, "Assessment of Chemotherapy Induced Ovarian Failure Using Serum Anti￾Mullerian Hormone in Premenopausal Breast Cancer Patients", Zagazig University, Faculty of Medicine, 2024 More
Tweet